Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

被引：191

作者：

Phillips, Elizabeth J. ^{[1
]}

Sukasem, Chonlaphat ^{[2
,3
]}

Whirl-Carrillo, Michelle ^{[4
]}

Mueller, Daniel J. ^{[5
,6
]}

Dunnenberger, Henry M. ^{[7
]}

Chantratita, Wasun ^{[8
,9
]}

Goldspiel, Barry ^{[10
]}

Chen, Yuan-Tsong ^{[11
,12
]}

Carleton, Bruce C. ^{[13
,14
]}

George, Alfred L. ^{[15
]}

Mushiroda, Taisei ^{[16
]}

Klein, Teri ^{[4
]}

Gammal, Roseann S. ^{[17
,18
]}

Pirmohamed, Munir ^{[19
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Pharmacogen & Personalized Med,Dept Pathol, Bangkok, Thailand

[3] Ramathibodi Hosp, Fac Med, Somdech Phra Debaratana Med Ctr, Lab Pharmacogen, Bangkok, Thailand

[4] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[5] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada

[6] Univ Toronto, Dept Psychiat & Pharmacol & Toxicol, Toronto, ON, Canada

[7] NorthShore Univ HealthSyst, Ctr Mol Med, Evanston, IL USA

[8] Mahidol Univ, Ramathibodi Hosp, Fac Med, Virol Lab,Dept Pathol, Bangkok, Thailand

[9] Mahidol Univ, Ramathibodi Hosp, Ctr Med Genom, Bangkok, Thailand

[10] NIH, Pharm Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA

[11] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan

[12] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA

[13] Univ British Columbia, Fac Med, Dept Pediat, Div Translat Therapeut, Vancouver, BC, Canada

[14] BC Childrens Hosp, Res Inst, Vancouver, BC, Canada

[15] Northwestern Univ, Dept Pharmacol, Feinberg Sch Med, Chicago, IL 60611 USA

[16] RIKEN, Ctr Integrat Med Sci, Lab Pharmacogen, Yokohama, Kanagawa, Japan

[17] MCPHS Univ, Dept Pharm Practice, Boston, MA USA

[18] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[19] Univ Liverpool, Dept Pharmacol, Liverpool, Merseyside, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 04期

基金：

加拿大健康研究院; 英国医学研究理事会; 加拿大创新基金会; 美国国家卫生研究院;

关键词：

STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADVERSE DRUG-REACTIONS; CYTOTOXIC T-CELLS; HLA-B-ASTERISK-1502; ALLELE; B GENOTYPE; HYPERSENSITIVITY REACTIONS; CUTANEOUS REACTIONS; JAPANESE PATIENTS; THAI POPULATION;

D O I：

10.1002/cpt.1004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

引用

页码：574 / 581

页数：8

共 50 条

[41] The clinical pharmacogenetics implementation consortium (CPIC): facilitating the adoption of pharmacogenetics into routine clinical practice and the electronic health record.
Caudle, Kelly E.
Hoffman, James M.
Whirl-Carrillo, Michelle
Haidar, Cyrine E.
Crews, Kristine R.
Klein, Teri E.
Relling, Mary V.
PHARMACOTHERAPY, 2014, 34 (10): : E251 - E252
[42] Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
Caudle, K. E.
Rettie, A. E.
Whirl-Carrillo, M.
Smith, L. H.
Mintzer, S.
Lee, M. T. M.
Klein, T. E.
Callaghan, J. T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 542 - 548
[43] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes
Gonsalves, Stephen G.
Dirksen, Robert T.
Sangkuhl, Katrin
Pulk, Rebecca
Alvarellos, Maria
Vo, Teresa
Hikino, Keiko
Roden, Dan
Klein, Teri E.
Poler, S. Mark
Patel, Sephalie
Caudle, Kelly E.
Gordon, Ronald
Brandom, Barbara
Biesecker, Leslie G.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1338 - 1344
[44] Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines
Pritchard, Daryl
Patel, Jai N.
Stephens, Lindsay E.
McLeod, Howard L.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (12) : 993 - 1005
[45] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
Crews, Kristine R.
Monte, Andrew A.
Huddart, Rachel
Caudle, Kelly E.
Kharasch, Evan D.
Gaedigk, Andrea
Dunnenberger, Henry M.
Leeder, J. Steven
Callaghan, John T.
Samer, Caroline Flora
Klein, Teri E.
Haidar, Cyrine E.
Van Driest, Sara L.
Ruano, Gualberto
Sangkuhl, Katrin
Cavallari, Larisa H.
Muller, Daniel J.
Prows, Cynthia A.
Nagy, Mohamed
Somogyi, Andrew A.
Skaar, Todd C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 888 - 896
[46] Pgxtools: A New Pharmacogenetic Analysis Tool Integrated with the Clinical Pharmacogenetics Implementation Consortium Database
Yuan, David Y.
Park, Jun H.
Li, Zhenyu
Lee, Hyun U.
Rack, Maxwell
Hwang, David M.
Fu, Lei
JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (06): : S11 - S12
[47] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Hicks, J. K.
Swen, J. J.
Thorn, C. F.
Sangkuhl, K.
Kharasch, E. D.
Ellingrod, V. L.
Skaar, T. C.
Mueller, D. J.
Gaedigk, A.
Stingl, J. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (05) : 402 - 408
[48] Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice
van Westrhenen, R.
van Schaik, R. H. N.
van Gelder, T.
Birkenhager, T. K.
Bakker, P. R.
Houwink, E. J. F.
Bet, P. M.
Hoogendijk, W. J. G.
van Weelden-Hulshof, M. J. M.
FRONTIERS IN PHARMACOLOGY, 2021, 12
[49] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy (vol 102, pg 45, 2017)
Moriyama, B.
Obeng, A. O.
Barbarino, J.
Penzak, S.
Henning, S.
Scott, S.
Agundez, J.
Wingard, J.
McLeod, H.
Klein, T.
Cross, S.
Caudle, K.
Walsh, T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 349 - 349
[50] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α-Based Regimens
Muir, A. J.
Gong, L.
Johnson, S. G.
Lee, M. T. M.
Williams, M. S.
Klein, T. E.
Caudle, K. E.
Nelson, D. R.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (02) : 141 - 146

← 1 2 3 4 5 →